{"analyses":[{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.85","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\< 1%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.63"},{"ciLowerLimit":"0.28","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.54","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\< 1%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.39"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.87","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\< 1%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.63"},{"ciLowerLimit":"0.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.59","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\>= 1%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.45"},{"ciLowerLimit":"0.30","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.53","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\>= 1%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.40"},{"ciLowerLimit":"0.66","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\>= 1%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.90"},{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.71","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\< 5%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.57"},{"ciLowerLimit":"0.33","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.53","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\< 5%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.42"},{"ciLowerLimit":"0.57","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.94","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\< 5%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.73"},{"ciLowerLimit":"0.27","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.60","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\>= 5%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.40"},{"ciLowerLimit":"0.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.54","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\>= 5%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.35"},{"ciLowerLimit":"0.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.38","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\>= 5%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.87"},{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.67","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\< 10%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.54"},{"ciLowerLimit":"0.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.54","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\< 10%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.43"},{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\< 10%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.80"},{"ciLowerLimit":"0.28","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.73","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression \\>= 10%","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.46"},{"ciLowerLimit":"0.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.49","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression \\>= 10%","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.28"},{"ciLowerLimit":"0.34","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.09","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression \\>= 10%","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.61"},{"ciLowerLimit":"0.49","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.52","estimateComment":"HR of Nivolumab vs. Ipilimumab in participants with PD-L1 expression not evaluable at baseline","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.86"},{"ciLowerLimit":"0.30","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.89","estimateComment":"HR of Nivolumab+Ipilimumab vs. Ipilimumab in participants with PD-L1 expression not evaluable at baseline","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.51"},{"ciLowerLimit":"0.33","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.09","estimateComment":"HR of Nivolumab+Ipilimumab vs. Nivolumab in participants with PD-L1 expression not evaluable at baseline","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Hazard Ratio (HR)","paramValue":"0.60"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.76","upperLimit":"5.39","value":"2.83"},{"groupId":"OG001","lowerLimit":"6.93","upperLimit":"26.68","value":"11.17"},{"groupId":"OG002","lowerLimit":"2.66","upperLimit":"2.86","value":"2.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"113"}],"units":"Participants"}],"title":"PD-L1 < 1% (n=117, 123, 113)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.11","upperLimit":"27.66","value":"16.20"},{"comment":"Upper 95% Confidence Interval was not reached.","groupId":"OG001","lowerLimit":"9.72","upperLimit":"NA","value":"16.72"},{"groupId":"OG002","lowerLimit":"2.83","upperLimit":"4.17","value":"3.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"155"},{"groupId":"OG002","value":"164"}],"units":"Participants"}],"title":"PD-L1 >= 1% (n= 171, 155, 164)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.96","upperLimit":"6.87","value":"5.32"},{"groupId":"OG001","lowerLimit":"8.31","upperLimit":"22.18","value":"11.17"},{"groupId":"OG002","lowerLimit":"2.76","upperLimit":"3.02","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"210"},{"groupId":"OG002","value":"202"}],"units":"Participants"}],"title":"PD-L1 < 5% (n= 208, 210, 202)"},{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached.","groupId":"OG000","lowerLimit":"9.46","upperLimit":"NA","value":"22.34"},{"comment":"Upper 95% Confidence Interval was not reached.","groupId":"OG001","lowerLimit":"9.72","upperLimit":"NA","value":"22.11"},{"groupId":"OG002","lowerLimit":"2.79","upperLimit":"4.21","value":"3.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"75"}],"units":"Participants"}],"title":"PD-L1 >= 5% (n= 80, 68, 75)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.09","upperLimit":"8.87","value":"5.62"},{"groupId":"OG001","lowerLimit":"8.02","upperLimit":"18.14","value":"11.10"},{"groupId":"OG002","lowerLimit":"2.76","upperLimit":"3.02","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"232"},{"groupId":"OG002","value":"223"}],"units":"Participants"}],"title":"PD-L1 < 10% (n= 229, 232, 223)"},{"categories":[{"measurements":[{"comment":"Upper 95% Confidence Interval was not reached.","groupId":"OG000","lowerLimit":"9.07","upperLimit":"NA","value":"21.98"},{"comment":"Median and upper 95% Confidence Interval were not reached.","groupId":"OG001","lowerLimit":"13.96","upperLimit":"NA","value":"NA"},{"groupId":"OG002","lowerLimit":"2.79","upperLimit":"5.59","value":"4.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"title":"PD-L1 >= 10% (n= 59, 46, 54)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.66","upperLimit":"6.93","value":"2.99"},{"groupId":"OG001","lowerLimit":"2.79","upperLimit":"20.04","value":"6.93"},{"groupId":"OG002","lowerLimit":"2.60","upperLimit":"6.41","value":"2.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"title":"PD-L1 Indeterminate/ Not Evaluable (n= 28, 36, 38)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"},{"groupId":"OG001","value":"314"},{"groupId":"OG002","value":"315"}],"units":"Participants"}],"description":"PD-L1 expression was defined as the percent of tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an IHC assay. Tumor biopsy specimens without measurable PD-L1 expression were classified as indeterminate if the staining was hampered for reasons attributed to the biology of the specimen and not because of improper specimen preparation or handling. Missing specimens, specimens that were not optimally collected (ie not evaluable), and all other specimens were classified as unknown. Participants must have been classified as PD-L1 \\>=5% or PD-L1 \\<5% per a verified IHC assay, or as indeterminate (ie not unknown), in order to be randomized.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab monotherapy 3 mg/kg intravenous (IV) once every 2 weeks (Q2W) until disease progression or unacceptable toxicity","id":"OG000","title":"Nivolumab"},{"description":"Nivolumab 1 mg/kg IV combined with Ipilimumab 3 mg/kg IV once every 3 weeks (Q3W) for 4 doses followed by nivolumab 3 mg/kg IV Q2W until disease progression or unacceptable toxicity","id":"OG001","title":"Nivolumab + Ipilimumab"},{"description":"Ipilimumab monotherapy 3 mg/kg IV Q3W for a total of 4 doses","id":"OG002","title":"Ipilimumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants with evaluable PD-L1 expression level at baseline","reportingStatus":"POSTED","timeFrame":"From randomization until disease progression or death from any cause, whichever occurs first (Assessed up to September 2016, approximately 39 months)","title":"Progression-Free Survival Based on PD-L1 Expression Level","type":"SECONDARY","unitOfMeasure":"months"}